HealthEquity, Inc. (NASDAQ:HQY) Given Consensus Rating of “Buy” by Brokerages

Shares of HealthEquity, Inc. (NASDAQ:HQY) have received an average recommendation of “Buy” from the twelve brokerages that are currently covering the company, MarketBeat reports. Twelve equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $101.42.

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research note on Tuesday, April 2nd. Raymond James raised their target price on shares of HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Friday, June 7th. Robert W. Baird lifted their price target on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. JMP Securities increased their price target on HealthEquity from $101.00 to $105.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 4th. Finally, Bank of America lifted their price objective on HealthEquity from $97.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, June 4th.

Insider Activity

In other news, Vice Chairman Stephen Neeleman sold 400 shares of HealthEquity stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total transaction of $34,000.00. Following the sale, the insider now directly owns 90,515 shares of the company’s stock, valued at $7,693,775. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 400 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $85.00, for a total transaction of $34,000.00. Following the completion of the sale, the insider now owns 90,515 shares of the company’s stock, valued at approximately $7,693,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the transaction, the chief executive officer now owns 126,635 shares in the company, valued at approximately $10,106,739.35. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,745 shares of company stock worth $5,482,530. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Several large investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC grew its holdings in HealthEquity by 22.7% in the first quarter. Lindbrook Capital LLC now owns 698 shares of the company’s stock worth $57,000 after purchasing an additional 129 shares during the period. Xponance Inc. increased its position in HealthEquity by 1.2% in the 4th quarter. Xponance Inc. now owns 12,269 shares of the company’s stock valued at $813,000 after buying an additional 147 shares in the last quarter. O Shaughnessy Asset Management LLC raised its stake in HealthEquity by 3.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 5,219 shares of the company’s stock worth $426,000 after buying an additional 197 shares during the period. KLR Investment Advisors LLC boosted its holdings in HealthEquity by 4.2% in the fourth quarter. KLR Investment Advisors LLC now owns 5,914 shares of the company’s stock worth $392,000 after acquiring an additional 241 shares in the last quarter. Finally, Capstone Investment Advisors LLC grew its stake in HealthEquity by 7.0% in the fourth quarter. Capstone Investment Advisors LLC now owns 3,710 shares of the company’s stock valued at $246,000 after acquiring an additional 243 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $84.74 on Wednesday. The firm has a market cap of $7.37 billion, a P/E ratio of 92.11, a price-to-earnings-growth ratio of 1.38 and a beta of 0.55. The business’s 50 day moving average is $80.49 and its 200-day moving average is $77.34. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.44. HealthEquity has a 1-year low of $59.02 and a 1-year high of $87.72.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.08. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. The firm had revenue of $262.39 million for the quarter, compared to analysts’ expectations of $258.56 million. Equities research analysts predict that HealthEquity will post 2.13 earnings per share for the current year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.